Igc Pharma, Inc. · AMEX:IGC
Igc Pharma — Investor Presentation (January 2024)
29 slides from Igc Pharma's investor presentation, January 2024
Slide 1: IGC Pharma Jan 2024
(E IGCPHARMA Jan, 2024 NYSE American: IGC
Slide 2: Safe Harbor
SAFE HARBOR The matters discussed in this presentation include forward-looking statements about the business prospects of IGC Pharma, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes, or similar expressions.
Slide 3: Company Overview
C OM PANY OVERVIEW • Our focus is treating Alzheimer’s disease (AD) through our growing pipeline of five drug assets • Lead therapeutic candidate IGC-AD1 is currently in a 146- person Phase 2b trial for agitation in dementia due to Alzheimer’s. IGC-AD1 is a CB1r partial agonist that reduces neuroinf
Slide 4: Alzheimer's Disease
ALZHEIM ER’S DISEASE 1in 9 13.8 M illion 65+ yrs. Americans with Americans with Alzheimer’s in 20231 Alzheimer’s by 20501 6.7 million $1Trillion Americans with Expected total expenses Alzheimer’s age (65+) in for Alzheimer’s and other dementias by 20502 20231 References: (1) Alzheimer’s Association
Slide 5: Investment Highlights
INVESTM ENT HIGHLIGHTS Two Patented and three patent pending investigational drug candidates targeting Alzheimer’s All showing favorable pre-clinical attributes towards Alzheimer’s disease pathology IGC-AD1 is currently in Phase 2B with data milestones expected in mid- 2024 Leading artificial intell
Slide 6: Vertically Integrated Operations
VERTICALLY INTEGRATED OPERATIONS Potomac, MD. Vancouver, WA Colombia India Headquarters cGMP Manufacturing Licensed R&D facilities Accounting and and Processing facility Analytics Overcoming Operational Barriers to Entry • Licensed phytocannabinoid grow facilities • Approved licenses • Standardized
Slide 7: AD Pipeline Overview
AD PIPELINE OVERVIEW ASSET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONE TARGETS neuroinflammation, neurotransmitter Topline data IGC-AD1 imbalance, inflammasome-3 and AD pathology Spring 2024 TARG ETS Aβ PLAQUES Tox study data mid 2024 TGR-63 (Early- Moderate Stage Alzheimer’s) TARGETS neuroinflamm
Slide 8: Agitation in Alzheimer's
AGITATION IN ALZHEIMER’S Agitation: excessive motor activity, verbal aggression, or physical aggression that is severe enough to impair personal relationships, social functioning, and/or daily activities1. Agitation starts early in AD and increases in severity as the disease progresses2. 4 0 - 8 0 %
Slide 9: Our Solution
OUR SOLUTION The Promise of IGC-AD1 A patent-protected compound in Phase 2B trials that targets agitation in Alzheimer’s disease Two APIs that target neuroinflammation, neurotransmitter imbalance, CB1r agonism and inflammasome- 3, all implicated in agitation in AD IGC-AD1 can potentially reduce agit
Slide 10: Two APIs That Target Multiple Pathways
TWO APIs THAT TARGET MULTIPLE PATHWAYS Focused on relieving pathological alteration due to agitation in AD Agitation in AD Treatment with IGC-AD1 Deficient in CB1 receptor function increases agitation animals1 ; CB1 activity at earlier AD stages is higher in Partial agonist targets CB1 receptor hipp
Slide 11: IGC-AD1 Phase I Trial Completed
IGC-AD1 PHASE I Safety, Tolerability, Agitation, NPS TRIAL C OM PLETED No life-threatening or serious adverse Multiple Ascending Dose (MAD) study to evaluate events at any dosing level safety and tolerability of IGC-AD1 in participants with AD & NPS (Neuropsychiatric Symptoms) using the NPI (Neurops
Slide 12: Results on NPS: Neuropsychiatric Symptoms Measured by NPI Scores
RESULTS ON NPS: NEUROPSYCHIATRIC SYMPTOMS MEASURED BY NPI SCORES Total NPI 35 .0 ** 31.5 30 .0 Results on NPS: Neuropsychiatric 25 .0 ** Symptoms Measured by 22.2 NPI Scores Average Total NPI 20.0 Baseline ** 16.0 Patients taking IGC-AD1 14.8 * Day 15 15.0 intervention showed an overall 12.4 improve
Slide 13: Agitation Results
AGITATION RESULTS NPI Agitation 5.0 4.7 4.5 4.3 4.2 4.0 3.5 3.0 3.0 At three different doses, Average NPI 2.5 Baseline agitation improved both Day 15 clinically and statistically (p 2.0 1.5 <.05) 1.5 1.4 1.0 0.5 0.0 Cohort 1 Cohort 2 Cohort 3 13
Slide 14: Potential of IGC-AD1 Beyond Agitation: Pre-clinical Results
POTENTIAL OF IGC-AD1 BEYOND AGITATION PRE-CLINICAL RESULTS ON AD CELL LINES Decreased plaques and decreased pTau: • Inhibits the aggregation of amyloid plaque • Reduces phosphorylated tau (pTau) • Enhances mitochondrial function • Non-toxic. Repeated low dosing over 48 hours is non- toxic J. Pineal.
Slide 15: Memory Improved in AD Mouse Model
POTENTIAL OF IGC-AD1 BEYOND AGITATION MEMORY IMPROVED IN AD (APP/PS1) MOUSE MODEL AD model mice dosed with the active ingredient in IGC- AD1 had significantly improved times and fewer errors in a Morris Water Maze test than those in the control group • The maze uses spatial cues for mice to navigate
Slide 16: Ongoing IGC-AD1 Phase II Trial
ON GOING IGC- AD1PHASE II TRIAL Placebo Controlled, Double Blind, Randomized, Multi Site Phase II protocol seeks to show that IGC-AD1 is effective, compared to placebo, in lowering agitation in participants with Alzheimer’s Objective • Evaluate if IGC-AD1 is superior to placebo in reducing agitation
Slide 17: IGC Pharma at the Forefront of AI-Integrated Pharmaceutical Research
IGC PHARMA AT THE FOREFRONT OF AI-INTEGRATED PHARMACEUTICAL RESEARCH IGC is partnered with leading Artificial Intelligence research center CINFONIA at the University of Los Andes Partnership aims to leverage deep learning algorithms and generative AI to analyze variations in disease signatures among
Slide 18: TGR-63: A Promising Path-Breaking Molecule
TGR-63 A PROMISING PATH-BREAKING MOLECULE • India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) created the TGR-63 molecule • IGC acquired exclusive rights to TGR-63 from JNCASR AD DRUG CANDIDATE 2 researchers in 2022 • Pre-clinical testing demonstrates that TGR-63 holds po
Slide 19: Naphthalene Monoimides
NAPHTHALENE MONOIMIDES • Naphthalene Monoimides are candidates to modulate A𝛽42 aggregation and associated toxicity. • TGR-63 demonstrated higher capacity to inhibit A𝛽42 TGR-63 aggregation (A), higher capacity to dissolve Aβ42 aggregates (B) and increased PC12 cell viability (C) when compared to…
Slide 20: The Promise of TGR-63: Reduction of Plaque in Mouse Model
The Promise of TGR-63: Reduction of Plaque in Mouse Model TGR-63 effectively reduced the amyloid burden in the mice cortex and hippocampus. WT DAPI AD +TGR63 +TGR63 DAPI OC DAPI OC Before administration TGR63 administration After administration AD/WT characterization Behavioral study Immunohistochem
Slide 21: TGR-63 Improved Behavior in a Mouse Model
TGR-63-Improved Behavior In a Mouse Model TGR-63 improved cognitive performance in APP/PS1 and Wild Type mice. The dose administered was 5 mg/kg body weight. Open field test TGR-63 treated mice had a lower locomotion in the field, indicating improved behavior. Adv. Therap. 2021, 4, 2000225 NYSE Amer
Slide 22: TGR-63 Improved Memory in a Mouse Model
TGR-63 Improved memory in a Mouse Model Novel object identification test Adv. Therap. 2021, 4, 2000225 TGR-63 treated mice had a higher exploration of the novel object. Morris Water M aze TGR-63 treated mice learned the location of the target and had less error rate than non treated mice.
Slide 23: TGR-63 to IGC-AD2 Timeline
TGR-63 TO “IGC-AD2” TIMELINE Early-Stage Preclinical FDA Review and Drug Preclinical Clinical Trials studies and Drug Post – M arket Development studies (IGC-AD2) Monitoring Development Target Identified and Established the Licensing of TGR-63 validated (JNC ASR) Proof of C oncept Phase-2 Clinical T
Slide 24: First Mover Advantage with Intellectual Property
FIRST MOVER ADVANTAGE WITH INTELLECTUAL PROPERTY FOREIGN PATENT US- PATENTS TARGET DES C RIPTION PATENTS APPLIC ATIONS GRANTED GRANTED • Alzheimer's Disease (IGC-AD1) Composition & Method for treating CNS Disorders 7 1 1 • Alzheimer's Disease (IGC-AD1) Composition & Method for treating CNS Disorders
Slide 25: Potential to Drive Significant Value
POTENTIAL TO DRIVE SIGNIFICANT VALUE NORTH AMERICA AND EUROPE ITEM Year 1 Year 2 Year 3 Individuals with AD 15M 15M 15M Agitation in AD (76%) 11M 11M 11M % adoption of drug (IGC- 3% 5% 10% AD1) Annual Price/Patient of drug $1,200 – $2,400 $1,200 – $2,400 $1,200 – $2,400 Estimated Revenue $0.4B – $0.
Slide 26: Senior Scientific Trial Team
SENIOR SCIENTIFIC TRIAL TEAM Dr. Varduhi Ghazaryan, MD, MPH Medical Director Dr. Saadia Shahnawaz, MD Medical Director Dr. Juan Manuel Orjuela, MD Scientific Neuropsychiatrist Management Jagadeesh Rao, PhD Principal Scientist Diego Rodriguez, PhD Senior Medicinal Chemist Evelyn Gutiérrez, Chem Eng.
Slide 27: Senior Scientific Advisors
SENIOR SCIENTIFIC ADVISORS Prof. Chuanhai Cao, PhD Professor of Pharmaceutical Science Inventors Prof. T Govindaraju, PhD, FRSC. Professor - Bioorganic Chemistry Dr. L. Elliot Hong, MD Professor Psychiatrist Dr. James Saunders, PhD Ret. Professor, Molecular Biology Scientific Advisors Jeffrey L. Cum
Slide 28: Caregiver Testimonial
Caregiver Testimonial From our Phase 1 IGC - AD1 study “I want to tell you a story that brought incredible joy to me. We participated in your Phase 1Clinical trial in Puerto Rico. After about a week of medication, one day I came home to find that she had made dinner and was dancing to music that she
Slide 29: Thank You
THANK YOU igc@imsinvestorrelations.com